Prucalopride vs. Motegrity: CIC Market Insights

  Published 9 months ago

Prucalopride, Motegrity’s bioequivalent, treats chronic idiopathic constipation in adults. Motegrity’s 2025 U.S. sales reached $184M. Lupin, a global pharma leader, develops complex generics and APIs.

  • Prucalopride treats chronic idiopathic constipation, a bioequivalent to Motegrity, with 2025 U.S. sales of $184M.
  • Lupin, a Mumbai-based pharma leader, specializes in complex generics, biotech products, and APIs for 100+ markets.
  • Prucalopride’s launch as a Motegrity alternative offers cost-effective treatment for CIC, enhancing market accessibility.

You might like these

Modi's 11 Years: Growth, Governance, Global Leadership

Markets Firm; FMCG Gains; IMF Ups India Outlook

Cupid Limited FY25: Mixed Results & Future Outlook

RBI Rejects Annapurna Finance's Bank License

IndiGo Hits Record High

ITD Cementation Q1 Profit Rises 21%

Indian Cement Stocks Dip on Monsoon Fears

News that matters the most ⚡